Related Experiment Video

Updated: Jul 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic

M Hughes1, G Y H Lip,

  • 1National Collaborating Center for Chronic Conditions, Royal College of Physicians, 11 St Andrew's Place, London, UK.

QJM : Monthly Journal of the Association of Physicians
|September 12, 2007
PubMed

Insights

Therapeutic anticoagulation for atrial fibrillation (AF) reduces stroke risk but increases bleeding. Key bleeding risk factors in AF patients include advanced age, uncontrolled hypertension, and prior cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) increases stroke risk, often managed with anticoagulation.
  • Anticoagulation therapy, while reducing stroke risk, carries a significant risk of bleeding complications.
  • Balancing anticoagulation benefits against bleeding risks is crucial for AF patient management.

Purpose of the Study:

  • To systematically review risk factors for anticoagulation-related bleeding in patients with atrial fibrillation.
  • To inform national guidelines for AF management by identifying key bleeding predictors.
  • To aid clinicians in optimizing anticoagulation therapy for AF patients.

Main Methods:

  • Systematic literature review of nine studies reporting anticoagulation-related bleeding in AF patients.
  • Analysis of patient characteristics identified as risk factors for bleeding complications.
  • Identification of significant and non-significant risk factors based on evidence.

Main Results:

  • Advanced age, uncontrolled hypertension, history of myocardial infarction or ischemic heart disease, cerebrovascular disease, anemia, prior bleeding history, and concurrent antiplatelet use are significant bleeding risk factors in AF patients.
  • Diabetes mellitus, controlled hypertension, and gender were not identified as significant risk factors.
  • Some identified bleeding risk factors are also indications for anticoagulation in AF.

Conclusions:

  • Several patient characteristics significantly increase the risk of bleeding during anticoagulation for AF.
  • Physicians must carefully weigh the benefits of anticoagulation against bleeding risks, considering individual patient factors.
  • Further research is needed to refine risk-benefit assessments for anticoagulation in AF management.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...